The 11 most recent market catalysts affecting $VVOS, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 8, 2026
Corporate Catalyst
Neutral
Impact 75
Vivos Therapeutics Announces Exchange Of $2,861,270 Of Streeterville Note Principal For 11,445,080 Common Shares At $0.25/Share
This headline indicates Vivos Therapeutics is undertaking a debt-to-equity conversion, exchanging $2.86 million of debt for common shares at $0.25 per share. While this reduces the…
Aug 28, 2026
Corporate Catalyst
Bullish
Impact 65
Vivos Therapeutics Announces Definitive Collaboration And Operating Agreements With South Palm Cardiovascular Associates To Form AIM Florida, Where It Expects 75% Interest; Palm Beach County Sleep Center Expected To Begin Treating Patients In Q1 2027
This headline represents a moderate corporate catalyst for Vivos Therapeutics. The formation of AIM Florida with a 75% interest indicates a significant strategic move to expand its…
Aug 25, 2026
Corporate Catalyst
Bullish
Impact 65
Vivos Therapeutics Announces 212% Rise YoY Over Most Recent Six-Week Period In Its New Obstructive Sleep Apnea Patient Referrals At Its Nevada Sleep & Airway Medicine Centers
Vivos Therapeutics reported a substantial 212% year-over-year increase in new OSA patient referrals at its Nevada centers, with weekly referrals growing nearly five-fold since June…
Aug 14, 2026
Corporate Catalyst
Bullish
Impact 92
Vivos Therapeutics Q2 EPS $(0.31) Beats $(0.36) Estimate, Sales $5.153M Miss $5.367M Estimate
Vivos Therapeutics' Q2 earnings report shows a mixed bag for investors. The company successfully narrowed its losses per share, beating analyst estimates and showing a significant …
Aug 11, 2026
Corporate Catalyst
Bullish
Impact 75
VVOS stock has given up its prior gain. Vivos Therapeutics shares were trading higher after the company announced an expanded partnership to deploy Greenway Health’s AI-by-design Novare platform across Vivos’ clinical operations.
The headline indicates a classic 'buy the rumor, sell the news' scenario or a market reassessment of the partnership's immediate value. While the expanded partnership with Greenway…
Aug 11, 2026
Corporate Catalyst
Bullish
Impact 75
Vivos Therapeutics shares are trading higher after the company announced an expanded partnership to deploy Greenway Health’s AI-by-design Novare platform across Vivos’ clinical operations.
The expanded partnership between Vivos Therapeutics and Greenway Health to deploy the Novare AI platform is a clear positive catalyst for Vivos, as evidenced by the immediate stock…
Aug 11, 2026
Corporate Catalyst
Bullish
Impact 65
Vivos Therapeutics Expands Greenway Health AI Partnership, Could Create Up To $9M In Potential Annual Value
Vivos Therapeutics has expanded its strategic engagement with Greenway Health to implement the AI-by-design Novare platform across its clinical operations, starting with Sleep Cent…
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 65
Vivos Therapeutics Announces USPTO Issues Patent No. 12,697,190 Broadening Protection For CARE Oral Devices Treating Obstructive Sleep Apnea
The patent broadens protection for Vivos Therapeutics' CARE oral devices, strengthening its intellectual property moat against competitors in the lucrative obstructive sleep apnea …
Aug 5, 2026
Corporate Catalyst
Neutral
Impact 65
UPDATE: Vivos Therapeutics Announces USPTO Issues Patent No. 12,697,190 Was Reported August 4, 2026
The issuance of a new patent to Vivos Therapeutics (VVOS) is a positive corporate catalyst. Patents protect a company's innovations, providing a competitive advantage and potential…
Aug 4, 2026
Corporate Catalyst
Neutral
Impact 55
Vivos Therapeutics Has Been Granted U.S. Patent Number 12,697,190 Titled "VIBRATIONAL ORAL APPLIANCE WITH MANDIBULAR ADVANCEMENTS"
Vivos Therapeutics has secured a new U.S. patent for its 'Vibrational Oral Appliance with Mandibular Advancements.' This is a positive development as it enhances the company's inte…
Jul 24, 2026
Corporate Catalyst
Neutral
Impact 65
VivoSim Labs Receives Nasdaq Noncompliance Notice, Gets Time Through Sept. 3 To Regain Compliance
VivoSim Labs (VVOS) has been notified by Nasdaq that it is not in compliance with the minimum bid price requirement for continued listing. This is a significant event for the compa…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.